Design Therapeutics Inc (DSGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -49,588 | -35,937 | -22,898 | -11,105 | -66,862 |
| Depreciation Amortization | -5,602 | -4,313 | -3,010 | -1,588 | -5,547 |
| Other Working Capital | -993 | -2,605 | -4,282 | -2,934 | 728 |
| Other Operating Activity | 13,078 | 9,610 | 6,491 | 3,188 | 13,121 |
| Operating Cash Flow | $-43,105 | $-33,245 | $-23,699 | $-12,439 | $-58,560 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 44,295 | 42,463 | 48,305 | 20,811 | 52,792 |
| PPE Investments | -340 | -340 | -356 | -195 | -256 |
| Investing Cash Flow | $43,955 | $42,123 | $47,949 | $20,616 | $52,536 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 513 | 250 | 249 | 20 | 724 |
| Financing Cash Flow | $513 | $250 | $249 | $20 | $724 |
| Beginning Cash Position | 21,200 | 21,200 | 21,200 | 21,200 | 26,500 |
| End Cash Position | 22,563 | 30,328 | 45,699 | 29,397 | 21,200 |
| Net Cash Flow | $1,363 | $9,128 | $24,499 | $8,197 | $-5,300 |
| Free Cash Flow | |||||
| Operating Cash Flow | -43,105 | -33,245 | -23,699 | -12,439 | -58,560 |
| Capital Expenditure | -340 | -340 | -356 | -195 | -256 |
| Free Cash Flow | -43,445 | -33,585 | -24,055 | -12,634 | -58,816 |